185 articles with Sanofi
RxMx Corp., in partnership with Sanofi, a global biopharmaceutical company, has won the "Best Healthcare Big Data Solution" award from the MedTech Breakthrough Awards for a program and series of technology products.
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine.
The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2021, without the physical presence of its shareholders, in accordance with the derogating measures adapting the rules governing the deliberation of general meetings taken by the French authorities as part of the fight against COVID-19, at the Company’s registered office in Paris, under the chairmanship of Serge Weinberg.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
GoodRx, America’s leading resource for healthcare savings, announced an integrated offering with global biopharmaceutical company Sanofi to streamline patient access to Sanofi discounts.
- Sanofi is the only company to leverage its manufacturing capacity and expertise to support three different COVID-19 vaccines to support the global supply of vaccines and help address the pandemic - Sanofi to manufacture up to 200 million doses of Moderna's vaccine in the U.S. starting in September 2021
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that it has received two milestone payments under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi.
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world's poorest countries access to 30 essential medicines
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were tr...
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
Global Blood Therapeutics, Inc. announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease : one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels
XNK Therapeutics partners with Karolinska Institutet on Phase II study in patients with multiple myeloma with support from Sanofi
XNK Therapeutics AB announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK's leading drug candidate in combination with Sanofi's anti-CD38 antibody Sarclisa.
Sanofi, Merck KGaA, Darmstadt, Germany, and More Than 500 Sites Join Inato in Making Clinical Research More Inclusive and Efficient
Inato, the first global industry marketplace that matches research sites to the right clinical trial protocols, today announced over 500 sites across more than 30 countries are participating in its Marketplace. Sanofi and Merck KGaA, Darmstadt, Germany have also joined the Marketplace, which will further Inato’s mission to accelerate the pace of medical innovation to improve people’s lives.
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format
All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.
Only biologic approved in Canada to treat severe asthma with type 2 / eosinophilic phenotype, or oral corticosteroid-dependent asthma
Sanofi's factory of the future named world's best overall facility by International Society for Pharmaceutical Engineering
Award recognizes innovative accomplishments in facility design, construction, and operation that are setting the standard for pharmaceutical facilities of the future
Perrigo Company plc, a leading global provider of Quality, Affordable Self-Care Products, announced that it has completed the acquisition of three Eastern European OTC skincare and hair loss treatment brands, Emolium®, Iwostin® and Loxon® from Sanofi.
Project aims to address systemic drivers of inequities in health that were exposed by the COVID-19 pandemic and improve long-term health outcomes in communities of color
Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease
$1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)